The DTWD2 Knockout HT29 Polyclonal Cells comprise a mixed population of HT29 human colorectal adenocarcinoma cells in which the DTWD2 gene has been disrupted via CRISPR/Cas9-mediated gene editing. This polyclonal knockout cell model enables loss-of-function studies of DTWD2 in a physiologically relevant intestinal epithelial context. The heterogeneous editing patterns across the population provide a robust tool for investigating the functional consequences of DTWD2 ablation without the constraints of single-cell clonal selection. Researchers can leverage this system to explore the role of DTWD2 in tRNA modification and its downstream impact on translation in colorectal cancer cells.
The HT29 cell line (ATCC HTB-38) is a widely used model of human colorectal adenocarcinoma, retaining many characteristics of intestinal epithelial cells, including the ability to differentiate under appropriate conditions. This cell line is a standard platform for studying colorectal cancer biology, drug responses, and signaling pathways relevant to gastrointestinal tumors. The use of HT29 as a host for DTWD2 knockout provides a well-characterized background to dissect the gene’s contribution to processes such as proliferation, differentiation, and tumorigenesis within the colorectal cancer milieu.
DTWD2 (DTW domain-containing protein 2) is a poorly characterized protein that shares sequence similarity with DTWD1, a known tRNA-modifying enzyme. Based on this homology, DTWD2 is predicted to participate in the wybutosine biosynthesis pathway, which involves a series of enzymatic steps catalyzed by TYW1, TYW2, TYW3, and TYW4. Its DTW domain may mediate a catalytic function on specific tRNA substrates, potentially modifying the phenylalanine tRNA to influence translation efficiency and fidelity. Although upstream regulators and interacting partners of DTWD2 remain unidentified, its putative role as a tRNA-modifying enzyme places it at the intersection of translation regulation and cellular homeostasis.
In colorectal adenocarcinoma cells, aberrant tRNA modification patterns have been linked to altered translation and malignant behavior. The DTWD2 knockout in HT29 cells provides a valuable model to investigate how loss of this predicted modifier affects translation dynamics and cancer cell phenotypes. By disrupting DTWD2 in a cell line that retains intestinal epithelial properties, researchers can assess its impact on processes such as growth factor signaling, stress responses, and metabolism that may be dysregulated in colorectal cancer. This model may help uncover whether DTWD2 contributes to tumor maintenance or progression through its effects on the translational machinery.
Applications of the DTWD2 knockout polyclonal cells include detailed analysis of tRNA modifications using HPLC or mass spectrometry to identify substrate changes. CRISPR knockout validation via sequencing and immunoblotting confirms target disruption, while protein interaction studies such as co-immunoprecipitation may help identify DTWD2-associating factors. Polysome profiling can reveal global translation changes, and cell proliferation and tumorigenesis assays in HT29 can link DTWD2 function to colorectal cancer phenotypes. Together, these approaches facilitate a comprehensive functional characterization. For further assistance, please contact Ascent Research.
